The current P/S multiple suggests that investors are pricing the company as a high-growth option rather than a mature medical device manufacturer. Given the absence of positive EBITDA or earnings, this valuation appears highly sensitive to the company's ability to maintain its 250% YoY revenue growth trajectory while simultaneously managing its cash burn.

The persistent decay in return on invested capital highlights the difficulty of scaling a specialized thin-film manufacturing process within a high-fixed-cost environment. Investors should monitor whether future revenue growth from the ablation generator can eventually offset the heavy R&D and clinical trial expenditures that currently suppress capital efficiency.

The high DIO and DSO figures indicate that the company's working capital is tied up in inventory and delayed payments, likely exacerbated by the distribution agreement with Zimmer Biomet. This lack of operational fluidity warrants further investigation into whether the company can optimize its supply chain as it moves toward higher-volume therapeutic product lines.

While the current ratio remains technically healthy, the absolute cash balance of approximately $6.5M against ongoing operating losses suggests a vulnerable liquidity profile. This necessitates a cautious outlook, as the company may be forced to seek dilutive financing to sustain its operations if revenue growth does not accelerate to self-funding levels.